ストックスクリーナーアプリを入手
157.69
2.38%
3.67
アフターアワーズ：
157.80
0.11
+0.07%
Belite Bio Inc Adr (BLTE) 最新ニュース
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences - markets.businessinsider.com
Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium - The Manila Times
Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium - GlobeNewswire Inc.
Responsive Playbooks and the BLTE Inflection - Stock Traders Daily
Price to earnings forward of Belite Bio, Inc. ADR – FWB:D01 - TradingView
BLTE Stock Price, Quote & Chart - ChartMill
Belite Bio, Inc. ADR Actuals & Estimates (NASDAQ:BLTE) - TradingView
Understanding the Setup: (BLTE) and Scalable Risk - Stock Traders Daily
Belite Bio (BLTE) After Its FDA Filing, Does The Stock Still Look Undervalued - Sahm
H.C. Wainwright Keeps Their Buy Rating on RegenXBio (RGNX) - The Globe and Mail
Top Executive Makes Major Move With Belite Bio Stock Sale - TipRanks
Belite Bio CMO Scholl sells over $1.45m in company shares - Investing.com Nigeria
Form 4 Belite Bio Inc ADR For: 22 June By Investing.com - Investing.com South Africa
Bioptima Ltd. tied to Belite Bio (BLTE) CMO sells 10,000 ADSs in open market - Stock Titan
Why Belite Bio (BLTE) Is Up 5.8% After Completing FDA NDA Submission For Tinlarebant - Sahm
BLTE News | BELITE BIO INCADR (NASDAQ:BLTE) - ChartMill
Dr. Hendrick Scholl sells 10,000 ADS as Form 144 filed (NASDAQ: BLTE) - Stock Titan
Belite Bio Soars After Key FDA Filing Milestone - TipRanks
Belite Bio CMO Scholl sells $1.4m shares from $137.61 to $145.02 - Investing.com India
Belite Bio (BLTE) CMO-affiliated entity sells 10,000 ADS, retains 32,946 - Stock Titan
BLTE (NASDAQ: BLTE) files Rule 144 notice to sell 10,000 ADS under vested RSUs - Stock Titan
Belite Bio stock price target maintained at $200 by H.C. Wainwright on NDA completion - Investing.com Nigeria
Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (BLTE), Climb Bio (CLYM) and Intuitive Surgical (ISRG) - The Globe and Mail
BLTE Reiterated by HC Wainwright & Co. -- Price Target Maintained at $200 - GuruFocus
The Technical Signals Behind (BLTE) That Institutions Follow - Stock Traders Daily
Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 - The Manila Times
Belite Bio (NASDAQ: BLTE) completes FDA NDA submission for tinlarebant in Stargardt disease - Stock Titan
Belite Bio Shares Surge on Drug Filing Hopes - TipRanks
Precision Trading with Belite Bio Inc (BLTE) Risk Zones - Stock Traders Daily
Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference - markets.businessinsider.com
Why Belite Bio Stock Is Sinking Again Today - TipRanks
Belite Bio Stock Tumbles as Wall Street Cools - TipRanks
Belite Bio Stock Slumps On Mounting Doubts - TipRanks
Belite Bio (BLTE) Hovers Near Resistance as Price Action Remains MutedBear Flag - The Legal Advocate
H.C. Wainwright Sticks to Their Buy Rating for Opko Health (OPK) - The Globe and Mail
BLTE - Finviz
Mizuho lowers Belite Bio stock price target to $215 on valuation - Investing.com UK
Mizuho lowers Belite Bio stock price target to $215 on valuation By Investing.com - Investing.com South Africa
Mizuho Adjusts Price Target on Belite Bio to $215 From $223, Maintains Outperform Rating - Moomoo
Technical Reactions to BLTE Trends in Macro Strategies - Stock Traders Daily
Belite Bio shares rise after first-quarter earnings outperform expectations (BLTE) - MSN
Benchmark reiterates Belite Bio stock rating on drug development progress By Investing.com - Investing.com Nigeria
Benchmark reiterates Belite Bio stock rating on drug development progress - Investing.com
Analysts Are Bullish on Top Healthcare Stocks: Belite Bio, Inc. ADR (BLTE), Centene (CNC) - The Globe and Mail
1.17%
2.48%
大文字化:
|
ボリューム (24 時間):